To include your compound in the COVID-19 Resource Center, submit it here.

Audentes inches up after pricing $75M IPO

Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) added $0.13 to $15.13 on its first day of trading

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE